Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Трансплантация печени, наличие трансплантированной печени, отмирание и отторжение трансплантата печени

Список литературы

  1. ифф, ., М. Соррел, У. Мэддрей Болезни печени по иффу: Цирроз печени и его осложнения. Трансплантация печени. – М: ГЭОТАР-Медиа, 2012.
  2. Трансплантология: руководство для врачей / Под ред В. И. умакова. – М: Медицинское информационное агенство, 2006. – 544 с.
  3. Bussutil, R. W., G. K. Klintmalm. Transplantation of the liver 3rd edition– Philadelphia: Elsevier Saunders, 2015. P. 1485
  4. Forman, L. M., J. D. Lewis, J. A. Berlin, H. I. Feldman, M. R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation / Forman, L. M., J. D. Lewis, J. A. Berlin, H. I. Feldman, M. R. Lucey //Gastroenterology. – 2002. – No 122 – 4 – P. 889-96.
  5. Loomba, R., A. K. Rowley, R. Wesley, K. G. Smith, T. J. Liang, F. Pucino, G. Csako Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis / Loomba, R., A. K. Rowley, R. Wesley, K. G. Smith, T. J. Liang, F. Pucino, G. Csako //Clin Gastroenterol Hepatol. – 2008. – No 6 – 6 – P. 696-700.
  6. Lucey, M. R. Liver transplantation in patients with alcoholic liver disease / Lucey, M. R. //Liver Transpl. - 2011.- No 17 - 7 - P. 751-9.
  7. Everson, G. T., Trotter J. F. Liver Transplantation. Challenging Controversies and Topics – USA: Humana Press, 2009. P.146.
  8. Ahmad, J. Hepatology and transplant hepatology – New York: Springer, 2011. P.427
  9. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2015 году.VIII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2016; XVIII (2): 5-23
  10. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al.Morbidity andmortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
  11. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int 2012;32:79-84.
  12. Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int 2012;32:1407-1414.
  13. Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown, Jr., Michael Fallon. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation, DOI 10.1002/hep.26972
  14. Yates WR, Martin M, LaBrecque D, Hillebrand D, Voigt M, Pfab D. A model to examine the validity of the 6-month abstinence criterion for liver transplantation. Alcohol Clin Exp Res 1998;22:513–517.
  15. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–1800.
  16. Pavel, M. C., & Fuster, J. (2018). Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World journal of gastroenterology, 24(32), 3626-3636.
  17. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699
  18. Supriya S. Patel, Amanda K. Arrington, Shaun McKenzie, et al., “Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States,” International Journal of Hepatology, vol. 2012, Article ID 253517, 7 pages, 2012. https://doi.org/10.1155/2012/253517.
  19. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008;21:1107–1117.
  20. Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: A systematic review. J Surg Oncol. 2017;116:288– 297. https://doi.org/10.1002/jso.24671
  21. Andres, A., Oldani, G., Berney, T., Compagnon, P., Line, P. D., & Toso, C. (2018). Transplantation for colorectal metastases: on the edge of a revolution. Translational gastroenterology and hepatology, 3, 74. doi:10.21037/tgh.2018.08.04
  22. Andre Gorgen, Hala Muaddi, Wei Zhang, Ian McGilvray, Steven Gallinger, and Gonzalo Sapisochin, “The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases,” Canadian Journal of Gastroenterology and Hepatology, vol. 2018, Article ID 9531925, 7 pages, 2018. https://doi.org/10.1155/2018/9531925.
  23. Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013;257:800–806.
  24. EASL Clinical Practice Guidelines: Liver transplantation Journal of Hepatology , Volume 64 , Issue 2 , 433 – 485
  25. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60:1268– 1289
  26. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88–98, e3; quiz e14.
  27. Российское трансплантологическое общество, «Национальные клинические рекомендации «Трансплантация печени», 2016 г.
  28. Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown, Jr., Michael Fallon. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation, DOI 10.1002/hep.26972
  29. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012;57:203–212
  30. Rodríguez-Castro KI, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation. 2012 Dec 15;94(11):1145-53. doi: 10.1097/TP.0b013e31826e8e53.
  31. Российское трансплантологическое общество, «Национальные клинические рекомендации «Трансплантация печени», 2016 г.
  32. Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown, Jr., Michael Fallon. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation, DOI 10.1002/hep.26972
  33. EASL Clinical Practice Guidelines: Liver transplantation Journal of Hepatology , Volume 64 , Issue 2 , 433 - 485
  34. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179–190.
  35. An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registrybased matched case-control study. Circulation 2014;130:1353–1362.
  36. Bernal W, Martin-Mateos R, Lipcsey M, Tallis C, Woodsford K, McPhail MJ, et al. Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease. Liver Transpl 2014;20:54–62.
  37. Wray C, Scovotti JC, Tobis J, Niemann CU, Planinsic R, Walia A, et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transplant 2013;13:184–191
  38. Umeda N, Kamath PS. Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res 2009;39:1020–1022.
  39. Koch DG, Fallon MB. Hepatopulmonary syndrome. Curr Opin Gastroenterol 2014;30:260–264.
  40. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37: 192–197
  41. Pastor CM, Schiffer E. Therapy Insight: hepatopulmonary syndrome and orthotopic liver transplantation. Nat Clin Pract Gastroenterol Hepatol 2007;4:614–621.
  42. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258–1264.
  43. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008;8:2445–2453.
  44. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461–1468.
  45. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007;13:875– 885
  46. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012;56:810–818.
  47. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011;60:702–709.
  48. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010;52: 605–613.
  49. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008;8:2243–2251.
  50. Cruz Jr RJ, Dew MA, Myaskovsky L, Goodpaster B, Fox K, Fontes P, et al. Objective radiologic assessment of body composition in patients with endstage liver disease: going beyond the BMI. Transplantation 2013;95: 617–622.
  51. Dick AA, Spitzer AL, Seifert CF, Deckert A, Carithers Jr RL, Reyes JD, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009;15:968–977.
  52. Durand F, Buyse S, Francoz C, Laouenan C, Bruno O, Belghiti J, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014;60:1151–1157.
  53. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. HEPATOLOGY 2002;35:105- 109.
  54. Wibaux C, Legroux-Gerot I, Dharancy S, Boleslawski E, Declerck N, Canva V, et al. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine 2011;78:387–391.

  1. Alcalde Vargas A, Pascasio Acevedo JM, Gutierrez Domingo I, Garcia Jimenez R, Sousa Martin JM, Ferrer Rios MT, et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. Transplant Proc 2012;44:1496–1498
  2. O’Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014;14:779–787
  3. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009;50:2022–2033.
  4. Fagiuoli S, Colli A, Bruno R, Craxi A, Gaeta GB, Grossi P, et al. Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. J Hepatol 2014;60:1075–1089.
  5. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol 2007;41:403–411.
  6. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26–42.
  7. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353–358.
  8. Falguera M, Trujillano J, Caro S, Menendez R, Carratala J, Ruiz-Gonzalez A, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009;49:409–416.
  9. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–1754.
  10. Lenz P, Conrad B, Kucharzik T, Hilker E, Fegeler W, Ullerich H, et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study. Gastrointest Endosc 2009;70:480–487.
  11. Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A. Biliary candida infections in primary sclerosing cholangitis. J Hepatol 2006;45: 711–716.
  12. Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009;9:S7–S18.
  13. Samuel D, Weber R, Stock P, Duclos-Vallee JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008;48:697–707.

  1. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012;57:203–212.
  2. Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl 2015;21:572–580.
  3. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91– 96.
  4. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871.
  5. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5: 307–313.
  6. Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl 2006;12: 440–447
  7. Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006;12 (12 Suppl 3):S128-S136.
  8. Goldberg, D. S., & Olthoff, K. M. (2014). Standardizing MELD Exceptions: Current Challenges and Future Directions. Current transplantation reports, 1(4), 232-237.
  9. Song GW, Lee SG. Living donor liver transplantation. Curr Opin Organ Transplant 2014; 19: 217-22.
  10. Karnsakul W, Intihar P, Konewko R, et al. Living donor liver transplantation in children: a single North American center experience over two decades. Pediatr Transplant 2012; 16: 486-95.
  11. National Institute for Health and Clinical Excellence. Living donor liver transplantation. Interventional procedure guidance 194.2011. http://www.nice.org.uk/guidance/IPG194/Guidance/pdf
  12. Gelas T, McKiernan PJ, Kelly DA, et al. ABO incompatible pediatric liver transplantation in very small recipients: Birmingham's experience. Pediatr Transplant 2011; 15: 706-11.
  13. Wu J, Ye S, Xu X, et al. Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. PLoS One 2011; 6:e16521.
  14. Kluger MD, Guarrera JV, Olsen SK, et al. Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database. Transplantation 2012; 94: 526-31.
  15. Kim JM, Kwon CH, Joh JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor. J Hepatol 2014 ; 59: 1215-22.
  16. Protocols and guidelines for children undergoing deceased donor liver transplantation in the UK. Liver Advisory Group; NHSBT 2010.
  17. Tannuri AC, Gibelli NE, Ricardi LR, et al. Living related donor liver transplantation in children. Transplant Proc 2011; 43: 161-4.
  18. Ueda M, Oike F, Ogura Y, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl 2006; 12: 1326-36.
  19. Living donor liver transplantation. British Transplantation Society United Kingdom Guidelines, July 2015.
  20. Guidelines for Antibody Incompatible Transplantation. Third edition. British Transplantation Society Guidelines, December 2015.
  21. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Ong JP, Oehler G, Krüger-Jansen C, Lambert-Baumann J, Younossi ZM. Clin Drug Investig. 2011; 31(4):213-20. doi: 10.2165/11586700-000000000-00000.
  22. Цирульникова И.Е. Трансплантация печени детям от АВО-несовместимых доноров // Диссертация на соискание ученой степени кандидата медицинских наук. 2014 г. 147 С.
  23. Цирульникова О.М., евченко О.П., Цирульникова И.Е., Ахаладзе Д.Г., Силина О.В., Джанбеков Т.А., Порунова А.К., Морозова В.В., Готье С.В. Способ десенсибилизации реципиента при АВО-несовместимой трансплантации печени детям раннего возраста – патент на изобретение №2582943 от 25.12.2014 г.
  24. Цирульникова О.М., евченко О.П., Цирульникова И.Е., Ахаладзе Д.Г., Силина О.В., Джанбеков Т.А., Порунова А.К., Морозова В.В., Готье С.В. Способ профилактики гуморального отторжения при АВО-несовместимой трансплантации печени детям раннего возраста – патент на изобретение №2580640 от 25.12.2014 г.
  25. Готье С.В. и соавт. Иммуносупрессия при трансплантации солидных органов // М. – Тверь: ООО «Издательство Триада», 2011. – 382 c.
  26. Killenberg, P. G., P.-A. Clavien Medical care of the transplant patient. Tonal Pre-, Intra- and Post- Operative Management – India: Blackwell Publishing, 2006. P.597
  27. Ильинский И.М., Можейко Н.П., калова Л.В., Цирульникова О.М., С.В. Готье. Диагностика острого отторжения аллотрансплантированной печени по схеме БАНФФ-1995 // Методические рекомендации.- Москва.- 2010.- 24 с.
  28. калова Л.В., Можейко Н.П., Ильинский И.М., Мойсюк Я.Г., Цирульникова О.М., Готье С.В. Диагностика острого отторжения по пункционным биоптатам аллотрансплантированной печени // Вестник трансплантологии и искусственных органов.- 2011.- № 3.- С. 15-19.
  29. International Working Party. Terminology for hepatic allograft rejection.- Hepatology.- 1995.- V. 22.- P. 648-654.
  30. Blakolmer K., Jain A., Ruppert K. et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow- up and evaluation of features for histopathological staging // Transplantation. – 2000. – V. 69. – P. 2330–2336.
  31. Готье С.В. и соавт. Инфекции в трансплантологии // М. – Тверь: ООО «Издательство Триада», 2010. – 384c.
  32. Katz, L. H., M. Paul, D. G. Guy, R. Tur-Kaspa Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta- analysis / Katz, L. H., M. Paul, D. G. Guy, R. Tur-Kaspa //Transpl Infect Dis. – 2010. – No 12 – 4 – P. 292-308.
  33. Lucey, M. R., N. Terrault, L. Ojo, J. E. Hay, J. Neuberger, E. Blumberg, L. W. Teperman Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation / Lucey, M. R., N. Terrault, L. Ojo, J. E. Hay, J. Neuberger, E. Blumberg, L. W. Teperman //Liver Transplantation. - 2013.- No 19 - 1 - P. 3-26.
  34. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009; 15: 1063– 1071.
  35. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017;67:1168–1176.
  36. Belli LS et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology. 2016; 65 (3): 524 – 553.
  37. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685–697.
  38. Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 2017;65:777–788.
  39. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterol, 2002; 122: 889–96.
  40. Selzner N, Renner E, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88: 1214–1221.
  41. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008; 8: 2426–2433.
  42. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterol. 2007; 132: 1746–1756.
  43. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679–687.
  44. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459–465.
  45. Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T.Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]. PMID:30807443
  46. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown Jr RS, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.
  47. Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q.Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis. 2019 Jan 7:e13047. doi: 10.1111/tid.13047. PMID:30615227
  48. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43:492–499.
  49. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830–836.
  50. Song ATW, Sobesky R, Vinaixa C, et al. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World Journal of Gastroenterology. 2016; 22 (18): 4547-4558. doi:10.3748/wjg.v22.i18.4547.
  51. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14: 58–66.
  52. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142:1373–1383.
  53. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon- based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6(7):1586 - 1599.
  54. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol . 2008; 49: 274– 287. doi: 10.1016/j.jhep.2008.05.002
  55. Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005;43:53– 59. 10.1016/j.jhep.2005.02.015.
  56. Zimmermann T, Bocher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif- Higer G, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007;20:583–590. 10.1111/j.1432-2277.2007.00481.x.
  57. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11. PMID:25386767
  58. Цирульникова О.М., Умрик Д.В., Милосердов И.А., Егорова Е.Т. Латыпов Р.А. Эффективность и безопасность препаратов прямого противовирусного действия у реципиентов печени с рецидивом хронического гепатита С 1 генотипа после трансплантации // Вестник трансплантологии и искусственных органов. – 2018. – Т. XX. - №4. – С. 21 – 27.
  59. Miuma S, Miyaaki H, Soyama A, Hidaka M, Takatsuki M, Shibata H, Taura N, Eguchi S, Nakao K. Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation. Hepatol Res. 2018 Nov;48(12):1045-1054. doi: 10.1111/hepr.13204. Epub 2018 Jul 19. PMID: 29908044
  60. Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X.Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.PMID:29886154
  61. Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation.Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec. PMID:30556034
  62. Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25. PMID: 29672891
  63. Ueda Y, Kobayashi T, Ikegami T, Miuma S, Mizuno S, Akamatsu N, Takaki A, Ishigami M, Takatsuki M, Sugawara Y, Maehara Y, Uemoto S, Seno H. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.J Gastroenterol. 2019 Feb 26. doi: 10.1007/s00535-019-01561-1. PMID:30806783
  64. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May;63(5):1493-505. doi: 10.1002/hep.28446. Epub 2016 Mar 7. PMID:26754432
  65. Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q.Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis. 2019 Jan 7:e13047. doi: 10.1111/tid.13047. [Epub ahead of print] Review. PMID:30615227
  66. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2017;67:370–398.
  67. Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018 Sep;50(9):944-953. doi: 10.1016/j.dld.2018.03.032. Epub 2018 Apr 13. PMID: 29735294
  68. Fung J, Wong T, Chok K, Chan A, Cheung TT, Dai JW, Sin SL, Ma KW, Ng K, Ng KT, Seto WK, Lai CL, Yuen MF, Lo CM. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology. 2017 Oct;66(4):1036-1044. doi: 10.1002/hep.29191. Epub 2017 Aug 26. PMID: 28370215
  69. Darweesh SK, Gad AA, Akroof K, ElLatif ZA.Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety. Eur J Gastroenterol Hepatol. 2019 Feb 4. doi: 10.1097/MEG.0000000000001377. [Epub ahead of print]. PMID:30724767.
  70. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013 Jun;108(6):942-8. doi: 10.1038/ajg.2013.111. Epub 2013 Apr 30. PMID:23629601

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*